Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (25)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Oka, K.
Right arrow Articles by Takahara, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oka, K.
Right arrow Articles by Takahara, S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2000) 15: 689-695
© 2000 European Renal Association-European Dialysis and Transplant Association

A clinicopathological study of IgA nephropathy in renal transplant recipients: beneficial effect of angiotensin-converting enzyme inhibitor

Kazumasa Oka, Enyu Imai, Toshiki Moriyama, Yoshitaka Akagi, Akio Ando, Masatsugu Hori, Akihiko Okuyama, Kiyohide Toki, Masahiro Kyo, Yukito Kokado and Shiro Takahara

Departments of Internal Medicine and Therapeutics and Urology, Osaka University Graduate School of Medicine, Sakurabashi Circulate Organ Clinic, School of Health and Sport Sciences, Osaka University, Osaka, Japan

Background. Prolonging the survival of transplant kidneys is a major task of modern nephrology. It has recently been shown that deteriorating renal function and substantial graft loss were observed in 55% of renal allograft recipients with recurrent IgA nephropathy (IgAN) at long-term follow-up. To gain a useful insight into the therapeutic approach towards protecting allograft kidneys from deteriorating graft function, we compared the histological characteristics of post-transplant IgAN to primary IgAN and investigated the effects of an ACE inhibitor.

Methods. Twenty-one patients with post-transplant IgAN and 63 patients with primary IgAN were included in the histopathological study. The effectiveness of angiotensin-converting enzyme (ACE) inhibitor treatment in post-transplant IgAN was also studied in 10 patients.

Results. The prevalence of glomeruli with adhesions and/or cellular crescents in primary IgAN was significantly greater than in post-transplant IgAN (P<0.05), but the proportion of glomeruli with segmental sclerosis was similar in both groups. The rate of global obsolescence, and the degree of interstitial fibrosis in post-transplant IgAN were significantly greater than in primary IgAN (P<0.05). The degree of glomerular obsolescence and the severity of interstitial fibrosis correlated with the severity of glomerular lesion in primary IgAN, but not in post-transplant IgAN. In primary IgAN, glomerular diameter significantly correlated with the proportions of glomerular obsolescence, but not in post-transplant IgAN, suggesting that allograft kidneys may be in a hyperfiltration state.

Both the blood pressure and the urinary protein excretion significantly improved after ACE-inhibitor treatment (P<0.001).

Conclusion. In post-transplant IgAN, histopathological lesions indicative of acute inflammatory insults were suppressed, and glomerular hypertrophy, which may relate to haemodynamic burden such as hyperfiltration, was prominent. Preliminary study of ACE-inhibitor treatment in 10 patients showed favourable effects. A future long-term follow-up study is required to establish the effectiveness of ACE inhibitors in treatment of post-transplant IgAN.

Keywords: ACE inhibitors; graft function loss; hyperfiltration; kidney allograft; post-transplant IgA nephropathy

Correspondence and offprint requests to: Enyu Imai MD, PhD, Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine (A8), 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
A. E. Courtney, P. T. McNamee, W. E. Nelson, and A. P. Maxwell
Does angiotensin blockade influence graft outcome in renal transplant recipients with IgA nephropathy?
Nephrol. Dial. Transplant., December 1, 2006; 21(12): 3550 - 3554.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
A. Chandrakantan, P. Ratanapanichkich, M. Said, C. V. Barker, and B. A. Julian
Recurrent IgA nephropathy after renal transplantation despite immunosuppressive regimens with mycophenolate mofetil
Nephrol. Dial. Transplant., June 1, 2005; 20(6): 1214 - 1221.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
J. Floege
Recurrent glomerulonephritis following renal transplantation: an update
Nephrol. Dial. Transplant., July 1, 2003; 18(7): 1260 - 1265.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.